Vimarsana
Biggest News Aggregation in the World

Page 15 - Bige News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bige. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bige Today - Breaking & Trending Today

iShares North American Natural Resources ETF (BATS:IGE) Sets New 1-Year High at $38.35 - Vimarsana News

iShares North American Natural Resources ETF (BATS:IGE) Sets New 1-Year High at $38.35

IShares North American Natural Resources ETF (BATS:IGE – Get Rating)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $38.35 and last traded at $38.23, with a volume of 96428 shares traded. The stock had previously closed at $37.66. iShares North American Natural Resources ETF […]

Don't Fear Testing for, and De-labeling, Penicillin Allergy - Vimarsana News

Don't Fear Testing for, and De-labeling, Penicillin Allergy

Use this simple proactive approach to remove the burden of penicillin allergy from patients who are mislabeled.

iShares North American Natural Resources ETF (BATS:IGE) Sets New 52-Week High at $38.35 - Vimarsana News

iShares North American Natural Resources ETF (BATS:IGE) Sets New 52-Week High at $38.35

IShares North American Natural Resources ETF (BATS:IGE – Get Rating)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $38.35 and last traded at $38.23, with a volume of 96428 shares. The stock had previously closed at $37.66. iShares North American Natural Resources ETF Stock […]

Biomarkers for Treatment Response Evaluated in Children With CSU - Vimarsana News

Biomarkers for Treatment Response Evaluated in Children With CSU

The results add to 'current understanding of the role of different biomarkers in treatment response,' in this population, according to the lead study author.

FDA to Review Dupilumab for Chronic Spontaneous Urticaria - Vimarsana News

FDA to Review Dupilumab for Chronic Spontaneous Urticaria

The application for FDA approval for CSU is based on data from a pair of phase 3 trials in two different populations.